Glaukos Corporation logo

GKOS

Glaukos Corporation

$50.64

Earnings Summary

Revenue
$67.68Mn
Net Profits
$5.38Mn
Net Profit Margins
7.94%

Highlights

Revenue:

Glaukos Corporation’s revenue fell -0.42% since last year same period to $67.68Mn in the Q1 2022. On a quarterly growth basis, Glaukos Corporation has generated -7.59% fall in its revenue since last 3-months.

Net Profits:

Glaukos Corporation’s net profit jumped 132.65% since last year same period to $5.38Mn in the Q1 2022. On a quarterly growth basis, Glaukos Corporation has generated 124.58% jump in its net profits since last 3-months.

Net Profit Margins:

Glaukos Corporation’s net profit margin jumped 132.79% since last year same period to 7.94% in the Q1 2022. On a quarterly growth basis, Glaukos Corporation has generated 126.6% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Glaukos Corporation post its latest quarter earnings

EPS Estimate Current Quarter
-0.44
EPS Estimate Current Year
-0.44

Highlights

EPS Estimate Current Quarter:

Glaukos Corporation’s earning per share (EPS) estimates for the current quarter stand at -0.44 - a 12% jump from last quarter’s estimates.

EPS Estimate Current Year:

Glaukos Corporation’s earning per share (EPS) estimates for the current year stand at -0.44.

Key Ratios

Key ratios of the Glaukos Corporation post its Q2 2022 earnings

Return on Assets (ROA)
-0.05
Return on Equity (ROE)
-0.1
Dividend Per Share (DPS)
0

Highlights

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Glaukos Corporation’s return on assets (ROA) stands at -0.05.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Glaukos Corporation’s return on equity (ROE) stands at -0.1.

Dividend Per Share (DPS):

Glaukos Corporation declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-05
-0.5
-0.38
24%

Company Information

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent, its first MIGS device, in the United States in 2012, its next-generation iStent inject device in the United States in 2018, and most recently, the iStent inject W device in 2020. In corneal health, Glaukos' proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.

Organisation
Glaukos Corporation
Headquarters
San Clemente, California, US
Employees
653
Industry
Health Technology
CEO
Thomas Burns